Na Jenụwarị 22, 2025, "Ọgwụ Okike" bipụtara nsonaazụ nke Akeso mepụtara ọgwụ mgbochi PD-1/CTLA-4 nke nwere ọgwụ mgbochi abụọ nke PD-1/CTLA-4 n'onwe ya yana oxaliplatin na capecitabine maka ọgwụgwọ mbụ nke adenocarcinoma nke a na-apụghị ịgbasa n'ógbè ma ọ bụ nke a na-apụghị ịgbasa n'ime afọ 2025 na ọmụmụ ihe gbasara ahụike nke Phase III (COMPASION-15/AK104-302).E gosipụtara ihe si na nnyocha COMPASION-15 pụta na mbụ n'ọnụ na Nzukọ Kwa Afọ nke American Association for Cancer Research (AACR) nke afọ 2024.
Nke a bụ ọmụmụ nke usoro nke atọ nke placebo, nke a na-achịkwa n'usoro, nke a na-achịkwa n'usoro nke abụọ. Ndị ọrịa ruru eru bụ ndị toro eto nwere adenocarcinoma G/GEJ a na-agwọghị agwọ, nke a na-apụghị iwepụ, nke nwere ọganihu n'ógbè ma ọ bụ nke metastatic. E nyere ndị ọrịa nhọrọ 1:1 iji nweta cadonilimab (10 mg kg−1 kwa izu atọ) ma ọ bụ placebo tinyere chemotherapy (kwa izu atọ). Isi ihe njedebe bụ ndụ zuru oke (OS) na ndị mmadụ ebumnuche ịgwọ (ọkwa dị mkpa n'otu akụkụ, P = 0.025). Isi njedebe nke abụọ gụnyere OS na ndị ọrịa nwere akara PD-L1 jikọtara ọnụ nke dị mma ≥5, ndụ na-enweghị ọganihu, ọnụego nzaghachi ebumnuche, oge nzaghachi na nchekwa. Dịka ọ dị na 18 Ọgọst 2023, e nyere ndị ọrịa 610 sitere na ebe ọmụmụ ihe 75 na cadonilimab (n = 305) ma ọ bụ placebo (n = 305). Site na nleba anya etiti nke ọnwa 18.7, otu cadonilimab nwere OS etiti dị ogologo karịa (14.1 megide ọnwa 11.1; oke ihe egwu (HR) 0.66; oge ntụkwasị obi 95% (CI) 0.54–0.81; P < 0.001) karịa otu placebo. E mezuru isi njedebe mbụ. Nlanarị etiti na-enweghị ọganihu bụ ọnwa 7.0 megide ọnwa 5.3 (HR 0.53, 95% CI 0.44–0.65). OS etiti na ndị ọrịa nwere akara PD-L1 jikọtara ọnụ nke dị mma ≥5 bụ ọnwa 15.3 megide ọnwa 10.9 (HR 0.58, 95% CI 0.41–0.82). Ọnụego nzaghachi ebumnuche bụ 65.2% megide 48.9% yana oge nzaghachi etiti nke ọnwa 8.8 megide ọnwa 4.4. Ihe ọjọọ ndị metụtara ọgwụgwọ nke ọkwa ≥3 mere na 65.9% nke otu cadonilimab na 53.6% nke otu placebo, ihe kachasị bụ mbelata ọnụọgụ platelet, mbelata ọnụọgụ neutrophil na anaemia. Ọtụtụ n'ime ihe ọjọọ ndị metụtara ahụ ike bụ ọkwa 1 ma ọ bụ 2. Ahụghị ihe mgbaàmà nchekwa ọhụrụ. Cadonilimab gbakwunyere chemotherapy mere ka OS dịkwuo mma nke ukwuu yana profaịlụ nchekwa a na-achịkwa na ndị ọrịa nwere G/GEJ adenocarcinoma dị elu.
Ọgwụ Cadonilimab bụ ọgwụ immunotherapy PD-1/CTLA-4 nke a na-emepụta n'ụlọ. Na June 29, 2022, NMPA nke China enyela Cadonilimab nkwado ahịa maka ọgwụgwọ nke ndị ọrịa kansa cervical relatest maọbụ metastatic metastatic (R/M CC) ndị gara n'ihu ma ọ bụ mgbe ha gbasịrị ọgwụgwọ chemotherapy nke dabeere na platinum. Na Septemba 2024, a kwadoro ihe ngosi ọhụrụ maka cadonilimab maka ọgwụgwọ mbụ nke ndị ọrịa nwere adenocarcinoma nke a na-apụghị ịgbasa ma ọ bụ nke a na-apụghị ịgbasa ma ọ bụ nke a na-anaghị agbasa na mpaghara ahụ, yana fluoropyrimidine na chemotherapy nke dabere na platinum. Ugbu a, CDE anabatala ojiji ọgwụ ọhụrụ maka Cadonilimab yana chemotherapy nke dabere na platinum, yana ma ọ bụ na-enweghị bevacizumab, maka ọgwụgwọ mbụ nke kansa cervical na-adịgide adịgide, nke na-emegharị ugboro ugboro, maọbụ nke metastatic. Ọzọkwa, a na-eme ọtụtụ ọmụmụ ihe gbasara ahụike, gụnyere nnwale nkebi nke atọ maka ọgwụgwọ adjuvant na ndị ọrịa nwere nnukwu ihe egwu nke nlọghachi mgbe a gwọchara ha nke kansa hepatocellular, nke ọma.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Ntụaka
https://www.nature.com/articles/s41591-024-03450-4
Oge ozi: Febụwarị-21-2025